Alpha -Tocopherol Acetate Dl- Arginine Hydrochlori
| Evidence Level: L5 | Predicted Indications: 0 |
Table of Contents
- Alpha -Tocopherol Acetate Dl- Arginine Hydrochlori
- Multi-Component Vitamin-Mineral Complex Preparation: Research Assessment Report
Multi-Component Vitamin-Mineral Complex Preparation: Research Assessment Report
One-Sentence Summary
This candidate is a complex preparation containing 17 components, including multiple fat-soluble and water-soluble vitamins, minerals (chromium, vanadium), herbal extracts (Gymnema sylvestre), and arginine. The combination characteristics suggest potential relevance to metabolic or blood glucose control-related indications. However, the TxGNN model currently produces no predicted indications, and the preparation has not obtained marketing approval in Taiwan. Overall, the available data for analysis is extremely limited, making effective drug repurposing assessment impossible.
Quick Overview
| Item | Content |
|---|---|
| Original Indications | Not recorded |
| Predicted New Indications | None (TxGNN produced no predicted results) |
| TxGNN Prediction Score | None |
| Evidence Level | L5 (below L5; no model predictions, no actual research) |
| Taiwan Marketing Status | ✗ Not marketed |
| Number of Licenses | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently the TxGNN model produces no predicted indications for this preparation, making it impossible to perform mechanism-related analysis.
Based on component composition, this complex preparation contains Gymnema sylvestre leaf extract, vanadyl sulfate, chromium nicotinate, and other components. These components are related to blood glucose control and adjunctive management of type 2 diabetes in traditional applications and some research. However, this represents speculation at the component level, not based on the model’s predicted output.
As this preparation lacks a DrugBank ID and mechanism of action data is missing, formal drug repurposing indication assessment cannot be conducted without obtaining necessary data supplements.
Clinical Trial Evidence
Currently no related clinical trial registration data is available.
Literature Evidence
Currently no related literature data is available.
Taiwan Market Information
This preparation has not obtained any marketing authorization in Taiwan and has no relevant license data.
Safety Considerations
Please refer to the warnings and precautions in the product information of each component.
Conclusion and Next Steps
Decision: Hold
Rationale: The TxGNN model produced no predicted indications for this multi-component complex preparation. Combined with the absence of marketing authorization in Taiwan and missing mechanism of action data, the fundamental conditions for conducting drug repurposing assessment are not currently met.
To proceed, the following is needed:
- Resolve the missing DrugBank ID issue: This preparation contains 17 components. It is recommended to query DrugBank for each component separately (e.g., separately evaluating Gymnema sylvestre, vanadyl sulfate, arginine and other major active components)
- Clarify the preparation’s positioning: Confirm whether this complex preparation is a single branded product. If a brand name exists, query the TFDA or FDA NDC database using the brand name
- Supplement original indication data: Contact the drug holder or query the originally approved indications for each component
- Re-run TxGNN predictions: Re-input the model with individual components after separation (such as Gymnema sylvestre or vanadyl sulfate), which may yield meaningful prediction results
- Supplement safety data: Multi-component interaction assessment (particularly the potential interaction between phytonadione and arginine). This requires re-querying the DDI database after obtaining DrugBank IDs for the components
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.